Effects of and the Mechanism of Action of Calcium Antagonists and Other Antianginal Agents

  • A. Fleckenstein
  • G. Fleckenstein-Grün
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 90)

Abstract

It is one of the most important achievements in modern basic cardiology that many substances with a positive or negative inotropic effect on heart muscle act as promoters or inhibitors of the mediator function of Ca2+ions in excitation-contraction coupling. For instance, beta adrenergic stimulation with adrenaline, noradrenaline, or isoproterenol facilitates the transmembrane Ca2+influx during excitation. Splitting of ATP by the Ca2+-activated myofibrillar ATPase, and contractile tension development, are thereby augmented. Similarly, under the influence of cardiac glycosides, more Ca2+is made available to the contractile myofibrils. Conversely, a number of negative inotropic substances can inhibit excitation contraction coupling of heart muscle by a Ca2+-antagonistic effect.

Keywords

Cardiomyopathy Adrenaline Cardiol Propranolol Cataract 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fleckenstein A: die Bedeutung der energiereichen phosphate für kontraktilität und tonus des myokards. Verh Dtsch Ges Inn Med 70: 81–99, 1964.PubMedGoogle Scholar
  2. 2.
    Fleckenstein A, Döring HJ, Kammermeier H: Experimental heart failure due to inhibition of utilisation of high-energy phosphates. In: Proceedings of and International Symposium on the Coronary Circulation and Energetics of the Myocardium, Milan, 1966. Basle: Karger, 1967, pp 220–236.Google Scholar
  3. 3.
    Fleckenstein A, Kammermeier H, Döring HJ, Freund HJ: Zum Wirkungsmechanismus neuartiger koron-ardilatatoren mit gleichzeitig sauerstoff-einsparenden myokard-effekten, Prenylamin und Iproveratril. Z Kreisl Forsch 56: 716–744 and 839–853, 1967.Google Scholar
  4. 4.
    Fleckenstein A, Tritthart H, Flackenstein B, Herbst A, Grün G: A new group of competitive Ca-antagonists (Iproveratril, D-600, Prenylamine) with highly potent inhibitory effects on excitation — contraction coupling in mammalian myocardium. Pflügers Arch 307: R25, 1969.PubMedGoogle Scholar
  5. 5.
    Fleckenstein A: Calcium Antagonism in Heart and Smooth Muscle: Experimental Facts and Therapeutic Prospects. Monograph edited by John Wiley. New York: John Wiley, 1983.Google Scholar
  6. 6.
    Fleckenstein A: Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol 17: 149–166, 1977.CrossRefGoogle Scholar
  7. 7.
    Fleckenstein-Grün G: Control of coronary spasms by calcium antagonists. In: Godfraind T, Albertini A, Paoletti R (eds) Calcium modulators. Amsterdam: Elsevier Biomedical, 1982, pp 141–154.Google Scholar
  8. 8.
    Fleckenstein-Grün G, Fleckenstein A: Ca-dependent changes in coronary smooth muscle tone and the action of Ca-antagonistic compounds with special reference to Adalat. In: Lochner W, Braasch W, Kroneberg G (eds) New Therapy of Ischemic Heart Disease. 2nd International Adalat Symposium, Amsterdam, 1974. Berlin: Springer-Verlag, 1975, pp 66–75.Google Scholar
  9. 9.
    Fleckenstein-Grün G, Fleckenstein A: Calcium-ant-agonismus, ein grundprinzip der vasodilatation. In: Fleckenstein A, Roskamm H (eds) Calcium-Antagonismus. Proceedings of an International Symposium on Calcium Antagonism, Frankfurt, December 1978. Berlin: Springer-Verlag, 1980, pp 191–207.Google Scholar
  10. 10.
    Fleckenstein-Grün G, Fleckenstein A: Calcium antagonism, a basic principle in vasodilation. In: Zan-chetti A, Kirkler DM (eds) Calcium Antagonism in Cardiovascular Theapy: Experience with Verapamil. Proceedings of an International Symposium, Florence, 2–4 October 1980. Amsterdam: Excerpta Medica, 1981, pp 30–48.Google Scholar
  11. 11.
    Grün G, Fleckenstein A: Die elektromechanische Entkoppelung der glatten gefassmuskulatur als Grundprinzip der coronardilatation durch 4-(2’-nitrophenyl)-2,6-dimethyl-1,4, dihydropyridin- 3,5- dicarbonsäure-dimethylester (Bay a 1040, Nifedipin). Arzneimittel forsch 22: 334–344, 1972.Google Scholar
  12. 12.
    Fleckenstein A: Specific inhibitors and promoters of calcium action in the excitation — contraction coupling of heart muscle and their role in the production or prevention of myocardial lesions. In: Harris P, Opie L (eds) Calcium and the Heart. Proceedings of the Meeting of the European Section of the International Study Group for Research in Cardiac Metabolism, London, 6 September 1970. London: Academic Press, 1971, pp 135–188.Google Scholar
  13. 13.
    Fleckenstein A, Döring HJ, Janke J, Byon YK: Basic actions of ions and drugs on myocardial high-energy phosphate metabolism and contractility. In: Schmier J, Eichler O (eds) Handbook of Experimental Pharmacology. New series vol 16/3. Berlin: Springer-Verlag, 1975, pp 345–405.Google Scholar
  14. 14.
    Kohlhardt M, Bauer B, Krause H, Fleckenstein A: Differentiation of the transmembrane Na and Ca channel in mammalian cardiac fibres by the use of specific inhibitors. Pflügers Arch 335: 309–322, 1972.PubMedCrossRefGoogle Scholar
  15. 15.
    Kohlhardt M, Fleckenstein A: Inhibition of the slow inward current by nifedipine in mammalian ventricular myocardium. Naunyn-Schmiedebergs Arch Pharmacol 298: 267–272, 1977.PubMedCrossRefGoogle Scholar
  16. 16.
    Winegrad S: Studies of cardiac muscle with a high permeability to calcium produced by treatment with ethylenediamine-tetraacetic acid. J Gen Physiol 58: 71–93, 1971.PubMedCrossRefGoogle Scholar
  17. 17.
    Entmann ML, Allen JC, Bornet EP, Gillette PC, Wallick ET, Schwartz A: Mechanisms of calcium accumulation and transport in cardiac relaxing system (sarcoplasmic reticulum membranes): Effects of verapamil, D 600, X 537 A and A 23187. J Mol Cell Cardiol 4: 681–687, 1972.CrossRefGoogle Scholar
  18. 18.
    Nayler WG, Szeto J: Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle. Cardiovasc Res 6: 120–128, 1972.PubMedCrossRefGoogle Scholar
  19. 19.
    Watanabe AM, Besch HR Jr: Subcellular myocardial effects of verapamil and D-600: Comparison with propranolol. J Pharmacol Exp Ther 191: 241–251, 1974.PubMedGoogle Scholar
  20. 20.
    Frey M, Janke J: The effect of organic Ca-antagonists (verapamil, prenylamine) on the calcium transport system in isolated mitochondria of rat cardiac muscle. Pflugers Arch (Suppl) 359: R26, 1975. Google Scholar
  21. 21.
    Langer GA, Frank JS, Nudd LM, Seraydarian K: Sialic acid: Effect of removal on calcium exchangeability of cultuted heart cells. Science 193: 1013–1015, 1976.PubMedCrossRefGoogle Scholar
  22. 22.
    Watanabe AM, Besch HR Jr: The relationship between adenosine 3’,5’-monophosphate levels and systolic transmembrane calcium flux. In: Fleckenstein A, Dhalla NS (eds) Recent Advances in Studies on Cardiac Structure and Metabolism. Vol 5: Basic Functions of Cations in Myocardial Activity. Baltimore: University Park Press, 1975, pp 95–102.Google Scholar
  23. 23.
    Wollenberger A: The role of cyclic AMP in the adtenetgic control of the heart. In: Naylor WG (ed) Contraction and Relaxation in the Myocatdium. London: Academic Press, 1975, pp 113–190.Google Scholar
  24. 24.
    Williamson JR, Woodrow ML, Scarpa A: Calcium binding to cardiac sarcolemma. In: Fleckenstein A, Dhalla NS (eds) Recent Advances in Studies on Cardiac Strucure and Metabolism. Vol 5: Basic Functions of Cations in Myocardial Activity. Baltimore: University Park Press, 1975, pp 61–71.Google Scholar
  25. 25.
    Späh F, Fleckenstein A: Nachweis einer strengen quantitativen korrelation zwischen hemmung des tfansmembranären calcium-influx und der mechanischen Spannungsentwicklung des myokards unter dem einfluss verschiedener calcium-antagonisten. In: Fleckenstein A, Rokamm H (eds) Calcium-Antagonismus. Betlin: Springer-Verlag, 1980, pp 29–41.Google Scholar
  26. 26.
    Fleckenstein A: Myocardstoffwechsel und nekrose. In: Heilmeyer L, Holtmeier HJ (eds) In: VI Symposium “Herzinfarkt und Schock”, dtsch Ges f Fortschtitte auf dem Gebiet der Inneren Medizin, Freiburg, 8 November 1968. Stuttgart: Georg Thieme, 1986, pp 94–109.Google Scholar
  27. 27.
    Fleckenstein A, Doting HJ, Leder O: The significance of high-energy phosphate exhaustion in the etiology of isoproterenol-induced cardiac necrosis and its prevention by iproverattil, compound D-600, or prenylamine. In: Lamarche M, Royer R (eds) In: International Symposium on Drugs and Metabolism of Myocardium and Striated Muscle. Nancy: University of Nancy, 1969, pp 11–22.Google Scholar
  28. 28.
    Fleckenstein A, Janke J, Döring HJ, Leder O: Myocardial fibre necrosis due to intracellular Ca overload: A new principle in cardiac pathophysiology. In: Dhalla S (ed) Myocardial Biology. Recent Advances in Studies on Cardiac Structure and Metabolism, Vol 4. Baltimore: University Park Press, 1974, pp 563–580.Google Scholar
  29. 29.
    Fleckenstein A, Janke J, Döring HJ, Leder O: Key role of Ca in the production of noncoronarogenic myocardial necroses. In: Fleckenstein A, Rona G (eds) Pathophysiology and Morphology of Myocardial Cell Alterations. Recent Advances in Studies on Cardiac Structure and Metabolism, Vol. 6. Baltimore: University Park Press, 1975, pp 21–32.Google Scholar
  30. 30.
    Fleckenstein A, Janke J, Döring HJ, Pachinger O: Ca overload as the detetminant factor in the production of catecholamine-induced myocardial lesions. In: Bajusz E, Rona G (eds) Cardiomyopathies. Recent Advances in Studies on Cardiac Structute and Metabolism, vol 2. Baltimore: University Park Press, 1973, pp 455–466.Google Scholar
  31. 31.
    Lossnitzer K, Mohr W, Knorad A, Guggenmoos R: Hereditary cardiomyopathy in the Syrian golden hamstet: Influence of verapamil as calcium antagonist. In: Kaltenbach M, Loogen F, Olsen EGJ (eds) Cardio-myopathy and Myocardial Biopsy. Berlin: Springer-Verlag, 1978, pp 27–37.Google Scholar
  32. 32.
    Kaltenbach M, Hopf R, Keller M: Calciumantagonistische therapie bei hypertroph-obstruktiver kardio-myopathie. Dtsch Med Wochenschr 101: 1284–1287, 1976.PubMedCrossRefGoogle Scholar
  33. 33.
    Nayler WG, Grau A, Slade A: A protective effect of verapamil on hypoxic heart muscle. Cardiovasc Res 10: 650–662, 1976.PubMedCrossRefGoogle Scholar
  34. 34.
    Henry PD, Schuchleib R, Borda LJ, Roberts R, Williamson JR, Sobel BE: Effects of nifedipine on myocardial perfusion and ischemic injury in dogs. Circ Res 43: 372–380, 1978.PubMedGoogle Scholar
  35. 35.
    Nagao T, Matlib MA, Franklin D, Millard RW, Schwartz A: Effects of diltiazem, a calcium antagonist, on regional myocardial function and mitochondfia aftet brief coronary occlusion. J Mol Cell Cardiol 12: 29–43, 1980.PubMedCrossRefGoogle Scholar
  36. 36.
    Weishaar R, Ashikawa K, Bing RJ: Effect of diltiazem, a calcium antagonist, on myocatdial ischemia. Am J Cardiol 43: 1136–1143, 1979.CrossRefGoogle Scholar
  37. 37.
    Clark RE, Christlieb IY, Ferguson TB, Weldon CS, Marbarger JP, Sobel BE, Roberts R, Henry PD, Ludbrook PA, Biello D, Clark BK: Laboratory and initial clinical studies of nifedipine, a calcium antagonist for improved myocardial preservation. Ann Surg 193: 719–732, 1981.PubMedCrossRefGoogle Scholar
  38. 38.
    Wit AL, Ctanefield PF: Effect of verapamil on the sinoatrial and atfioventticular nodes of the rabbit and the mechanism by which it arrests reentrant attioven-tricular nodal tachycardia. Circ Res 35: 413–425, 1974.PubMedGoogle Scholar
  39. 39.
    Zipes DP, Fischer JC: Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog. Circ Res 34: 184–192, 1974.PubMedGoogle Scholar
  40. 40.
    Zipes DP, Mendez C: Action of manganese ions and tetrodotoxin on atrioventricular nodal transmembrane potentials in isolated rabbit hearts. Circ Res 32: 447–454, 1973.PubMedGoogle Scholar
  41. 41.
    Kohlhardt M, Figulla HR, Tripathi O: The slow membrane channel as the predominant mediator of the excitation process of the sinoatrial pacemaker cell. Basic Res Cardiol 71: 17–26, 1976.PubMedCrossRefGoogle Scholar
  42. 42.
    Tritthart H, Fleckenstein B, Fleckenstein A: Some fundamental actions of antiarrhythmic drugs on the excitability and contractility of single myocardial fibres. Naunyn-Schmiedebergs Arch Pharmacol 269: 212–219, 1971.PubMedCrossRefGoogle Scholar
  43. 43.
    Singh BN, Vaughan Williams EM: A fourth class of antidysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials and on other features of cardiac function. Cardiovasc Res 6: 109–119, 1972.PubMedCrossRefGoogle Scholar
  44. 44.
    Bender F: Die behandlung der tachykarden arrhythmien und der arteriellen hypertonic mit Isoptin. Arzneimittelforsch 20: 1310–1316, 1970.PubMedGoogle Scholar
  45. 45.
    Schamroth L, Krikler D, Garrett C: Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J 1: 660–662, 1972.PubMedCrossRefGoogle Scholar
  46. 46.
    Krikler D, Spurreil R: Verapamil in the treatment of paroxysmal supraventricular tachycardia. Postgrad Med J 50: 447–453, 1974.PubMedCrossRefGoogle Scholar
  47. 47.
    Spurrell R, Krikler D, Sowton E: Concealed bypasses of the atrioventricular tachycardia revealed by intracardiac electrical stimulation and verapamil. Am J Cardiol 33: 590–595, 1974.PubMedCrossRefGoogle Scholar
  48. 48.
    Spurrell R, Krikler D, Sowton E: Effects of verapamil on electophysiological properties of anomalous atrioventricular connexion in Wolff-Parkinson-White syndrome. Br Heart J 36: 256–264, 1974.PubMedCrossRefGoogle Scholar
  49. 49.
    Fleckenstein A, Frey M, Leder O: Prevention by calcium anatgonists of arterial calcinosis. In: Fleckenstein A, Hashimoto K, Herrmann M, Schwartz A, Seipel L (eds) New Calcium Antagonists: Recent Development and Prospects. Proceedings of the Diltiazem Workshop, Freiburg, 10 May 1982. Stuttgart: G Fischer Verlag, 1983, pp 15–31.Google Scholar
  50. 50.
    Fleckenstein A, Frey M, v Witzleben H: Vascular calcium overload: A pathogenic factor in arteriosclerosis and its neutralization by calcium antagonists. In: Kaltenbach M, Neufeld HN (eds) 5th International Adalat Symposium: New Theapy of Ischaemic Heart Disease and Hypertension. Proceedings, Berlin, 12–14 May 1982. Amsterdam: Excerpta Medica, 1983, pp 36–52.Google Scholar
  51. Fleckenstein A, v Witzleben H, Frey M, Milner TG: Prevention of cataracts of alloxan-diabetic rats by long-term treatment with verapamil. Pflügers Arch (Suppl) 391: R12. Google Scholar
  52. 52.
    Frey M, Keidel J, Fleckenstein A: Verhütung experimenteller gefäss-verkalkungen (Mönckeberg’s typ der arteriosklerose) durch calcium-antagonisten. In: Fleckenstein A, Roskamm H (eds) Calcium-Antagonismus. Proceedings of an International Symposium on Calcium Antagonism, Frankfurt, December 1978. Berlin: Springer-Verlag, 1980, pp 258–264.Google Scholar
  53. 53.
    Janke J, Hein B, Pachinger O, Leder O, Fleckenstein A: Hemmung arteriosklerotischer gefässprozesse durch prophylaktische behandlung mit MgCl2, KCL und organischen Ca++-antagonisten (quantitative Studien mit Ca45 bei ratten). In: Betz E (ed) Vascular Smooth Muscle. Proceedings of a Satellite Symposium 25th Congress International Union Physiological Sciences, Tübingen, 20–24 July 1971. Berlin: Springer-Verlag, 1972, pp 71–72.Google Scholar
  54. 54.
    Fleckenstein A, Grün G, Byon YK, Döring HJ, Tritthart H: The basic Ca antagonistic actions of nifedipine on cardiac energy metabolism and vascular smooth muscle tone. In: Hashimoto K, Kimura E, Kobayashi T (eds) New Therapy of Ischemic Heart Disease. First International Nifedipine (Adalat) Sym-posium, Tokyo, 1973- Tokyo: University of Tokyo, 1975, pp 31–44.Google Scholar
  55. 55.
    Fleckenstein A, Tritthart H, Döring HJ, Byon YK: Bay a 1040, ein hochaktiver Ca++-antagonistischer inhibitor der elektro-mechanischen koppelungspro-zesse im warmblüter-myokard. Arzneimittelforsch 22: 22–33, 1972.PubMedGoogle Scholar
  56. 56.
    Fleckenstein A, Fleckenstein-Grün G, Byon YK, Haastert HP, Späh F: Vergleichende Untersuchungen über die Ca-antagonistischen grundwirkungen von Niludipin (Bay a 7168) und Nifedipin (Bay a 1040) auf myokard, myometrium und glatte gefässmusku-latur. Arzneimittelforsch 29: 230–246, 1979.PubMedGoogle Scholar
  57. 57.
    Nakajima H, Hoshiyama M, Yamashita K, Kiyomoto A: Effect of diltiazem on electrical and mechanical activity of isolated cardiac ventricular muscle of guinea pig. Jn J Pharmacol 25: 383–392, 1975.Google Scholar
  58. 58.
    Fleckenstein A, Fleckenstein-Grün G, Byon YK: Fundamentale hertz- and gefässwirkungen des Ca++-antagonistischen koronartherapeutikums fendilin (SensitR). Arznemittelforsch 27: 562–571, 1977.Google Scholar
  59. 59.
    Fleckenstein-Grün G, Fleckenstein A, Byon YK, Kim KW: Mechanism of action of Ca2+-antagonists in the treatment of coronary disease with special reference to perhexiline maleate. In: Proceedings of the Symposium on Perhexiline Maleate, Strasbourg, 18 September 1976. Amsterdam: Excerpta Medica, 1978, pp 1–22.Google Scholar
  60. 60.
    Fleckenstein A: Experimentelle pathologie der akuten und chronischen herzinsuffizienz. Verh Dtsch Ges Kreisl-Forsch 34: 15–34, 1968.Google Scholar
  61. 61.
    Fleckenstein, A: Fundamental actions of calcium antagonists on myocardial and cardiac pacemaker cell membranes. In Weiss GB (ed). New Perspectives on Calcium Antagonists. Bethesda American Physiological Society, Clinical Physiological Series, 1981, pp 59–81.Google Scholar
  62. 62.
    Fleckenstein, A: Pharmacology and electrophysiology of calcium antagonists. In: Zanchettia. A Krikler DM (eds). Calcium Antagonism in Cardiovascular Therapy: Experience with Verapamil; Proceedings of an International Symposium on Calcium Antagonism in Cardiovascular Therapy, Florence, October 1980. Amsterdam-Oxford-Princeton: Excerpta Medica, 1981, pp 10–29.Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • A. Fleckenstein
  • G. Fleckenstein-Grün

There are no affiliations available

Personalised recommendations